Question · asked by 1 review
Montelukast vs placebo: Number of participants experiencing any serious adverse events
- Population
- Children with obstructive sleep apnoea (aged 15 years or younger)
- Intervention
- Montelukast
- Comparison
- placebo
- Outcome
- Number of participants experiencing any serious adverse events
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Montelukast vs placebo Serious adverse events (N experiencing event) · obstructive sleep apnoea in children The review found no eligible studies for this question. Anti‐inflammatory medications for obstructive sleep apnoea in children (2020) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anti‐inflammatory medications for obstructive sleep apnoea in children 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.